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AbsTrACT
background Until recently, determining penetrance 
required large observational cohort studies. Data from 
the exome aggregate consortium (exac) allows a 
Bayesian approach to calculate penetrance, in that 
population frequencies of pathogenic germline variants 
should be inversely proportional to their penetrance for 
disease. We tested this hypothesis using data from two 
cohorts for succinate dehydrogenase subunits a, B and 
c (SDHA–C) genetic variants associated with hereditary 
pheochromocytoma/paraganglioma (Pc/Pgl).
Methods two cohorts were 575 unrelated australian 
subjects and 1240 unrelated UK subjects, respectively, 
with Pc/Pgl in whom genetic testing had been 
performed. Penetrance of pathogenic SDHA–C variants 
was calculated by comparing allelic frequencies in cases 
versus controls from exac (removing those variants 
contributed by the cancer genome atlas).
results Pathogenic SDHA–C variants were identified in 
106 subjects (18.4%) in cohort 1 and 317 subjects (25.6%) 
in cohort 2. Of 94 different pathogenic variants from both 
cohorts (seven in SDHA, 75 in SDHB and 12 in SDHC), 13 
are reported in exac (two in SDHA, nine in SDHB and two 
in SDHC) accounting for 21% of subjects with SDHA–C 
variants. combining data from both cohorts, estimated 
lifetime disease penetrance was 22.0% (95% ci 15.2% to 
30.9%) for SDHB variants, 8.3% (95% ci 3.5% to 18.5%) 
for SDHC variants and 1.7% (95% ci 0.8% to 3.8%) for 
SDHA variants.
Conclusion Pathogenic variants in SDHB are more 
penetrant than those in SDHC and SDHA. Our findings 
have important implications for counselling and 
surveillance of subjects carrying these pathogenic 
variants.
InTroduCTIon
Phaeochromocytomas (PCs, tumours of the adrenal 
medulla) and paragangliomas (PGLs, tumours of 
sympathetic or parasympathetic ganglia) are highly 
heritable, with 14 PC/PGL susceptibility genes 
identified.1–3 Six of these genes were included 
in the American College of Medical Genetics 
recommendations for mandated reporting of inci-
dental findings from clinical exome and genome 
sequencing4 5: VHL, RET,  succinate dehydrogenase 
subunits B, C, D (SDHB, SDHC, SDHD) and 
SDHAF2. The high heritability of PC/PGL strongly 
suggests that germline genetic testing be consid-
ered for all affected individuals, enabling predictive 
genetic testing for at-risk relatives if a pathogenic 
variant is detected.6 7
Germline mutations in the SDH genes are 
the most common genetic cause of PC/PGLs 
(MIM:168000,605373,115310 and 614165), 
occurring in approximately 15% of cases.1–3 By 
comparison, the next most common associated 
genes are VHL (4%–10%), RET (1%–5%) and NFI 
(1%–5%). VHL and NF1 are associated with Von 
Hippel Lindau (MIM:193300) and neurofibro-
matosis type 1 (MIM:162200), respectively, that 
include PC/PGL as part of a broader syndrome.
Since PC/PGL are rare tumours,8 not only should 
pathogenic variants be individually extremely rare 
but their cumulative frequency within disease-asso-
ciated genes (if fully penetrant) should be <0.0001 
in large population cohorts (ie, population preva-
lence of 1/5000 with allele frequency of 1/10 000 
for autosomal dominant disease). Penetrance esti-
mates from cohort studies varies considerably for 
each gene, ranging from ~3% for NF1 mutations 
to 90% for SDHD mutations.6 7 As a corollary of 
the observed imperfect penetrance, the frequency 
of potentially pathogenic variants within the 
population should be higher than the empiric 
figure presented above. It is also appreciated that 
individual pathogenic variants in the same gene 
may have differing functional impact and hence 
penetrance, a good example being the BRCA1 
c.5096G>A (p.R1699Q) variant having moderate
penetrance as opposed to the highly penetrant
c.5095C>T (p.R1699W).9 This variable pene-
trance complicates genetic counselling.
Penetrance for SDHx variants has been somewhat 
controversial. Initial estimates suggested penetrance 
for SDHB variants of between 45% and 77% at ages 
40–60 years,10–12 likely inflated, however, by inclu-
sion of index cases. Subsequent analyses excluding 
index cases have suggested a much lower lifetime 
penetrance for SDHB variants of 22%–30%,11 13 14 
although Rijken et al15 have reported penetrance 
for SDHB variants of 42.1% (34.8%–49.5%) at 70 
years and Jochmanova et al16 reported penetrance 
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Table 1 SDHA-C variants in cases from cohorts 1 (Aus) and 2 (UK) and also present in ExAC 
Gene Variants† LoVd Id (26)
number of probands (allele frequencies, %) Allele frequencies in ExAC (-TCGA)
Aus (n=575) uK (n=1240) Combined, % Total, %
European (non-
Finnish), %
SDHA  c.91C>T, p.Arg31* SDHA_000013 3 (0.26) n/a 0.014 0.026
 c.512G>A, p.Arg171His Novel 1 (0.087) n/a 0.0009 0
 Non-ExAC variants 5 (0.43)
Total 9 (0.78) n/a 0.78 0.015 0.022
SDHB  c.79C>T, p.Arg27* SDHB_000150 2 (0.17) 8 (0.32) 0.28 0.001 0
 c.88delC, p.Gln30Argfs*47 SDHB_000017 3 (0.26) 7 (0.28) 0.28 0.0009 0.0018
 c.136C>T, p.Arg46* SDHB_000021 4 (0.35) 11 (0.44) 0.41 0.0019 0.0018
 c.268C>T, p.Arg90* SDHB_000001 14 (1.2) 8 (0.32) 0.61 0.001 0.0019
 c.423+1G>A SDHB_000047 2 (0.17) 3 (0.12) 0.14 0.0009 0.0018
 c.343C>T, p.Arg115* SDHB_000042 0 (0) 6 (0.24) 0.17 0.0019 0.0037
 c.649C>G, p.Arg217Gly novel 0 (0) 1 (0.04) 0.028 0.001 0.002
 c.688C>T, p.Arg230Cys SDHB_000058 0 (0) 1 (0.04) 0.028 0.0009 0.0018
 c.725G>A, p.Arg242His SDHB_000004 5 (0.43) 3 (0.12) 0.22 0.0028 0.0018
 Non-ExAC variants 60 (5.2) 239 (9.6) 8.20
Total 90 (7.8) 287 (11.6) 10.0 0.012 0.014
SDHC  c.77+2dupT SDHC_000049 0 (0) 1 (0.04) 0.028 0.0009 0.0018
 c.397C>T, p.Arg133* SDHC_000015 1 (0.087) 5 (0.2) 0.17 0.0028 0.0018
 Non-ExAC variants 6 (0.52) 24 (0.97) 0.83
Total 7 (0.61) 30 (1.2) 1.0 0.0038 0.0029
†RefSeq: for SDHA NG_012339.1, NM_004168.3; for SDHB NG_012340.1, NM_003000.2; for SDHC NG_012767.1, NM_003001.3.
ExAC, Exome Aggregate Consortium; SDHx, succinate dehydrogenase subunits A, B and C; TCGA, The Cancer Genome Atlas.
Bold values are totals.
of 49.80% (95% CI 29 to 74.9) at 85 years. Family-based pene-
trance studies in SDHB kindreds have suggested penetrance 
of 26%–35% by age 50 years.17–19 A large number of possible 
confounders might explain these differences, including referral 
bias, intensity of carrier screening, genotype–phenotype correla-
tion or other genetic and/or environmental modifiers. A recent 
study of a relatively small number of SDHA variants reported 
penetrance of 39% at 40 years, but significantly less (13%) when 
index cases were removed.20 Penetrance for SDHC variants is as 
yet unknown.
An elegant approach to estimating penetrance of pathogenic 
variants was recently proposed by Vassos et al21 and extended 
by Minikel et al22 and Stessman et al,23 using an algorithm that 
compares variant allelic frequency in disease cases to its frequency 
in large population control cohorts such as the Exome Aggregate 
Consortium (ExAC), and accounting for known disease preva-
lence and proportion of hereditary cases for that disease.
In this study, we tested the hypothesis that allelic frequencies 
for pathogenic SDHA–C variants present in ExAC would be 
inversely proportional to their penetrance, using two cohorts of 
PC/PGL subjects in whom genetic testing had been performed. 
We excluded SDHD variants from this analysis since this gene is 
unsuited to Bayesian methodology due to imprinting and subop-
timal coverage in whole exome sequencing.
METhods
Clinical methods
Australian patients with PC/PGL referred to the Cancer Genetics 
Diagnostic Laboratory, Royal North Shore Hospital, were tested 
for RET, VHL, SDHA, SDHB, SDHC and SDHD according to 
previously published methodology.24–26 Genetic testing was triaged 
initially by an in-house protocol and more recently according to 
PC/PGL Clinical Practice Guidelines,6 with the additional use of 
tumour SDHB immunohistochemistry27 to guide testing of SDH 
subunit genes. Testing of a sample was performed iteratively and 
stopped when a variant was identified and considered to be patho-
genic/likely pathogenic (P/LP) by one of the following criteria: (1) 
the variant was described as P/LP in a disease-specific database 
(ARUP, Leiden Open Variation Database (LOVD) or ClinVar); 
(2) null variant or missense variant predicted to be damaging or
deleterious by at least two in silico tools and a functional study to
support damaging effect (eg, in the case of SDHx variants, loss of
SDHB immunostaining in tumour) or (3) the variant was present in 
multiple affected family members. UK patients were analysed for
SDHB/SDHC/SDHD/VHL mutations by Sanger sequencing (until
2012) and then mostly by a next generation sequencing assay of
MAX, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127
or VHL.28SDHB and SDHC sequence variants were classified as
P/LP/benign/variants of uncertain significance by the reporting
diagnostic laboratory. The GenBank Accession numbers were as
follows: for SDHA NG_012339.1, NM_004168.3; for SDHB
NG_012340.1, NM_003000.2 and for SDHC NG_012767.1,
NM_003001.3.
Comparison of allele frequencies (table 1) between the Cohort 
Aus and Cohort UK was performed by G-test of Independence in 
DescTools R package V.0.99.24.
Northern Sydney Local Health District Human Research 
Ethics Committee (Executive)noted that this project involves 
the use of existing data for the purpose of publishing figures 
on the occurrence of pathogenic variants. All subjects had given 
written informed consent for clinical genetic testing. The data 
being used are de-identified. Based on this information and in 
accordance with the National Health and Medical Research 
Council National Statement 2007—Section 5.1.22, the NSW 
Supplement to the National Statement—Section 5.1.6 and 
NSW Health Guideline GL2007_020: Quality Improvement 
and Ethics Review: A Practice Guide for NSW, this project was 
assessed as activity not requiring full HREC review.
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LoVd search method
The LOVD (http://www. lovd. nl)29 was manually searched for 
variants in SDHA–C subunit genes and retrieved 59 unique vari-
ants in SDHA, 260 variants in SDHB and 66 variants in SDHC. 
Variants common both to LOVD and ExAC (http:// exac. broadin-
stitute. org) and absent from The Cancer Genome Consortium 
(ftp:// ftp. broadinstitute. org/ pub/ ExAC_ release/ release1/ subsets/ 
ExAC_ nonTCGA. r1. sites. vep. vcf. gz) were tabulated according 
to allelic frequency in ExAC.
Penetrance and CI calculation
Bayesian calculation of the conditional probability of disease 
(penetrance) given the genotype was performed using the 
following formula23:
 
P
(
D|G
)
=
P
(
G|D
)×P(D)
P
(
G|D
)×P(D)+P(G|D¯)×(1−P(D))
where D  = disease,  G  = genotype, and 
−
D  = absence of
disease.
The denominator, equivalent to P(G), is the sum of joint prob-
abilities of  G  with respect to both D  and 
−
D  which are mutually
exclusive and collectively exhaustive of all possible events.
 P
(
D|G
)
  is the penetrance (the probability of disease given a 
genotype);  P
(
G|D
)
  is the genotype frequency in cases;  P
(
G|D¯
)
is the allele frequency in ExAC and  P
(
D
)
  is the general popula-
tion prevalence for PC/PGL, assumed ~1/3000.8
CI was obtained on the binomial probability as described by 
Rosenfeld et al.30 Upper bound CI for penetrance using upper 
bound on  P
(
G|D
)
  and the lower bound on  P
(
G|D¯
)
 . Lower
bound CI for penetrance using lower bound on  P
(
G|D
)
  and the
upper bound on  P
(
G|D¯
)
 . Data from cases and from ExAC were
used to estimate these frequencies.
Figures were plotted by using a modification of Minikel et 
al,22 and source code is provided online at https:// github. com/ 
ericminikel/ prnp_ penetrance.
rEsuLTs
Cohort 1 consisted of 575 Australian subjects presenting with 
PC/PGL for whom genetic testing was performed between 
1998 and 2016. Overall, 172 subjects (29.9%) with PC/PGL 
were diagnosed with a P/LP variant in one of nine genes. P/LP 
SDHA–C variants were identified in 106 subjects (nine SDHA, 90 
SDHB and seven SDHC). By comparison, P/LP variants in other 
genes were: 36 SDHD, nine RET, 15 VHL, four TMEM127, one 
FH and one MAX.
Cohort 2 consisted of 1240 UK subjects presenting with PC/
PGL for whom genetic testing was performed between 2001 and 
2017.14 Overall, 446 subjects (36%) with PC/PGL were diag-
nosed with a P/LP variant in one of nine genes. P/LP SDHA–C 
variants were identified in 317 subjects (287 SDHB and 30 
SDHC) and P/LP variants in other genes were 96 SDHD, 25 
VHL, two RET, two FH, one TMEM127, two MAX and one 
SDHAF2.
We inferred pathogenicity for each variant from published 
evidence29 and/or based on segregation or loss of heterozygosity 
or the absence of protein on immunohistochemistry (table 1, 
online Supplementary table 1). Criteria for P/LP variants were 
consistent with standards for the interpretation of sequence vari-
ants issued by the American College of Medical Genetics and 
Genomics (ACMG).31
We compared SDHA–C variants considered P/LP in either 
cohort against the high confidence variant calls in the ExAC 
database from which The Cancer Genome Atlas (TCGA) cases 
had been removed (obtained from ftp:// ftp. broadinstitute. org/ 
pub/ ExAC_ release/ release1/ subsets/, 22 June 2017) in order to 
diminish the risk of confounding by disease inclusion in cases. 
The allelic frequency of 13 variants that are present in ExAC are 
shown in table 1 and those that are not reported in ExAC are 
shown in the online Supplementary table 1. For completeness, 
we have listed in online Supplementary table 2 all previously 
reported SDHA–C variants from ClinVar that are also present 
in ExAC.
For variants in SDHB and SDHC, allelic frequencies were not 
significantly different between Aus and UK cohorts: using G-test 
of independence, G=1.2858, 10 df, p=0.9995 and post hoc 
pairwise G-test found a coefficient value of 0.8897441 between 
the two cohorts. We therefore combined the two cohorts for 
subsequent analyses. We note that when all variants (including 
those not present in ExAC) were considered, SDHB variants 
were collectively more frequent in cohort 2 (23.2%) than in 
cohort 1 (15.6%) (table 1). This difference was not confined 
to a particular type of mutation (online Supplementary table 1) 
and therefore unlikely to be due to any systematic difference 
in variant detection method. The collective frequency of SDHC 
variants was similar in both cohorts (table 1).
Of these 13 P/LP SDHx variants in ExAC, all are individually 
rare with the exception of SDHA variant c.91C>T, p.Arg31* 
(frequency 1/3036). Although individually rare, when the popu-
lation frequencies for these variants were combined together 
(excluding SDHA p.Arg31*), the estimated population preva-
lence of these hereditary PGL syndromes assuming  complete 
penetrance would be 1/6000.
We next applied the principles described in Minikel et al22, 
using the algorithm described by Stessman et al23 and with CIs 
calculated as described by Rosenfeld et al30 to estimate the life-
time penetrance of PC/PGL for SDHA–C variants taking into 
account allelic frequencies in our cases versus ExAC controls 
and estimated population prevalence of these disorders. Our 
penetrance estimates are shown in figure 1: predicted lifetime 
penetrance for SDHB variants is 22.0% (95% (CI 15.2% to 
30.9%), for SDHC variants 8.3% (95% CI 3.5% to 18.5%) and 
for SDHA variants 1.7% (95% CI 0.8% to 3.8%). Penetrance 
estimates did not vary significantly by individual allele either 
in separate cohorts or in the combined analysis (online Supple-
mentary figure 1). Although population stratification is not rele-
vant when considering pathogenic variants causing monogenic 
disease (in the absence of a founder effect), nevertheless, to 
account for possible confounding by ethnicity, we also compared 
allelic frequencies in our cases against the European non-Finnish 
exome data from ExAC. As shown in the online Supplementary 
figure 2, exclusion of non-European/Finnish alleles from the 
control data set did not significantly alter our penetrance esti-
mates although did result in wider CIs due to inclusion of fewer 
variants (for SDHA 1.2%, 95% CI 0.5% to 2.7%; for SDHB 
20.1%, 95% CI 12.8% to 30.0% and for SDHC 10.4%, 95% CI 
3.4% to 27.6%.
dIsCussIon
We have systematically addressed the possibility of low pene-
trance alleles in hereditary PC/PGL syndromes, using a recently 
described approach for correlating penetrance with allelic 
frequency.22 Correct assignment of pathogenecity for genetic 
variants has become an urgent problem facing the clinical 
genetics community, particularly with increasing use of whole 
exome/genome sequencing technology.31 32 Our study has several 
notable results: first, P/LP SDHB, SDHC and SDHA variants are 
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Figure 1 estimated lifetime penetrance of pheochromocytoma/paraganglioma (Pc/Pgl) in subjects heterozygous for genetic variants in succinate 
dehydrogenase subunits a, B and c (SDHA, SDHB and SDHC) from cohorts 1 and 2 combined. the algorithm used to calculate these estimates is based on 
Minikel et al22 and takes into account allelic frequencies in cases versus exome aggregate consortium (exac) controls and estimated population prevalence 
of these disorders.
more common in ExAC than expected; second,our Bayesian esti-
mate of lifetime penetrance for SDHB variants is close to empiric 
data from cohort studies and third, SDHC and SDHA variants 
have low penetrance.
Although each are individually rare, the collective frequency 
of known P/LP SDHB, SDHC and SDHA variants in ExAC was 
highly surprising and may have several explanations: (1) these 
hereditary endocrine disorders are more common than previ-
ously thought due to the presence either of subpenetrant alleles 
or incomplete case ascertainment; (2) development of these 
disorders requires additional genetic modifiers, the absence of 
which diminishes disease risk in carriers of P/LP alleles; (3) the 
ExAC database is inadvertently enriched for PC/PGL subjects 
(unlikely) or (4) that the ExAC database contains sequencing 
errors (unlikely). On one hand, it is attractive to dismiss these 
findings as variant calling artefacts present in the ExAC data-
base; however, population frequency estimates for pathogenic 
BRCA mutations inferred in a similar fashion are extremely close 
to sequencing estimates from a randomly selected Australian 
patient pool in the Lifehouse study.33 Again, these estimates and 
population screening findings are at least twofold higher than 
previously perceived population estimates. That these vari-
ants are more common than expected is non-trivial, if whole 
exome/genome sequencing is performed at a population level, 
when apparently healthy subjects carrying so-called pathogenic 
alleles will outnumber subjects identified on the basis of disease 
expression34: if indeed present in 0.017% of the population, 
then ~4000 subjects in Australia and ~11 000 subjects in the 
UK are carrying these P/LP SDHx variants.
We deliberately excluded SDHD variants from our anal-
ysis, since this gene is unsuited to Bayesian methodology 
due to imprinting and suboptimal coverage in whole exome 
sequencing. (Only one of 37 different P/LP SDHD variants from 
our cohorts was present in ExAC, data not shown.) Paternally 
inherited SDHD variants are associated with high penetrance 
of disease35 and would therefore be expected to be rare in the 
general population.
The finding that SDHA c.91C>T, p.Arg31* occurs in ExAC 
at a population frequency >10−4 is at first glance surprising: 
several reports have shown an association between this variant 
with either PGLs or gastrointestinal stromal tumours36 37; it is 
more frequently reported in PGLs than expected by chance, and 
bona fide loss of function was inferred from tumoural loss of 
heterozygosity at this locus and by the absence of SDHA assessed 
by immunohistochemistry.37 However, familial disease appears 
to be rare in association with this variant20 consistent with low 
penetrance.
For SDHB variants, calculated lifetime penetrance estimates 
appear close to recent empiric data,11–14 and the lower pene-
trance estimates for SDHA and SDHC conform to our anecdotal 
experience. It is interesting to note that penetrance and risk of 
multifocal disease seem to be related, that is, ~30% subjects 
with SDHB variants will have more than one PGL or PC, 
whereas very few subjects with SDHA variants develop multi-
focal disease.20 This deserves further study with larger cohorts 
of specific genotypes.
Shah et al38 recently used whole genome sequence data from 
10 495 unrelated individuals (with replication in public data 
from more than 138 000 exomes/genomes in gnomAD) to study 
population frequency of pathogenic variants in ACMG-recom-
mended 59 gene-condition sets, including SDHB and SDHD. 
They found that SDHB and SDHD P/LP variants were more 
than 10-fold inflated in the population compared with expected 
population prevalence of hereditary PC/PGL, and with one 
possible explanation being that some variants may have been 
misclassified. The alternate explanation that the inflation is due 
to incomplete penetrance is supported by our data with some 
frequent variants being significantly inflated in two clinically 
ascertained datasets in a consistent manner. Those 13 SDHx 
variants in ExAC that we have observed in our PC/PGL cases 
all have very strong evidence of pathogenicity in LOVD and/or 
ClinVar. Indeed, 12 of these variants have a ClinVar star rating 
of 2 (multiple submitters with assertion criteria). Moreover, nine 
of these variants are loss-of-function (premature termination or 
splice site) variants. That these variants are more frequent in the 
population than expected for the corresponding disease prev-
alence can only mean either that they are subpenetrant and/or 
that the disease itself is more common than realised. The fact 
that our Bayesian estimates for SDHB are so close to empiric 
findings from recent cohort studies11–14 and to family-based 
studies17–19 gives us confidence that our estimates for SDHC and 
SDHA are also reliable.
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Our study has some important limitations. We deliberately 
chose a validation cohort from a population with close genetic 
similarity to the discovery cohort,39 and naturally our findings 
may not apply to populations with different ethnic backgrounds; 
indeed, it will be interesting to compare allelic frequencies of 
these variants in populations worldwide. These algorithms may 
underestimate penetrance for variants not present in ExAC; 
some studies12 14 15 have suggested that certain SDHB variants 
are more penetrant. With respect to using ExAC data as controls, 
we attempted to minimise confounding by using the data set 
from which TCGA cases had been removed; it is remotely 
possible that PC/PGL cases were inadvertently enriched in 
other cohorts contributing to ExAC (eg, within cardiovascular 
cohorts). Finally, it is possible that an iterative testing process 
may have missed combinations of pathogenic variants in two or 
more genes; although our subsequent experience using massively 
parallel sequencing approaches suggests that the presence of two 
germline pathogenic variants is rare (data not shown).
While our manuscript was under review, Maniam et al40 
reported a similar Bayesian approach to calculate penetrance for 
SDHA variants at 0.1%–4.9%, although their study was based 
on published series of SDHA cases rather than as we have done 
using PPGL case cohorts. Despite these differences in case ascer-
tainment, the similarity of penetrance estimates between the 
two studies is striking and consistent with our conclusion that 
pathogenic SDHA variants are likely to have low penetrance for 
disease expression.
We conclude that this approach of using population frequency 
of suspected P/LP variants in ExAC is extremely useful to vali-
date empiric calculations from cohort studies. Our data suggests 
that at least for P/LP variants present in ExAC, penetrance is 
approximately 22% for SDHB variants, 8.3% for SDHC vari-
ants and 1.7% for SDHA variants. Our findings will have critical 
value for genetic counselling and screening of subjects carrying 
these P/LP variants. By more robust stratification of risk, rational 
allocation of biochemical and imaging surveillance could reduce 
both the cost and anxiety associated with carrying a germline 
mutation.
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